Key Highlights
• Nuvectis Pharma (NASDAQ: NVCT) priced 5,000,000 shares at $20.00 per share in a firm commitment offering.
• Proceeds are expected to reach approximately $93 million, rising to $107 million if underwriters exercise a 30-day option for 750,000 additional shares.
• The offering closes July 1, 2026, under a shelf registration filed with the SEC in February 2026.
• Cantor Fitzgerald & Co. Serves as the sole underwriter for the transaction.
Nuvectis Pharma Secures Funding
Nuvectis Pharma (NASDAQ: NVCT) has finalized terms for a public stock offering, raising fresh capital to advance its clinical-stage pipeline. The biotech firm priced the deal at $20.00 per share, a key milestone for its financial strategy.
Offering Structure and Size
The company sold 5,000,000 shares of common stock in a firm commitment underwritten offering. Each share carries a par value of $0.00001, reflecting standard corporate accounting for biotech issuers. The transaction is set to close on July 1, 2026.
Underwriter Option and Proceeds
Underwriters led by Cantor Fitzgerald & Co. Hold a 30-day option to purchase up to 750,000 additional shares. If exercised, the offering’s total proceeds could reach approximately $107 million, up from the base $93 million expected at closing.
Shelf Registration Details
The registration became effective earlier this year, allowing the company to access capital markets efficiently.
Use of Capital
Nuvectis Pharma has not disclosed specific allocations for the proceeds but typically deploys such funds toward clinical trials, drug development, and operational expansion. The $93 million infusion provides runway for ongoing programs without immediate dilution concerns.
Market and Pipeline Context
The offering follows a period of pipeline progress for Nuvectis Pharma, which focuses on oncology and rare disease therapies. Investors are monitoring the impact of the capital raise on the company’s clinical timelines and regulatory filings.
Press Release Timeline
Nuvectis Pharma issued two press releases on June 29, 2026, announcing the launch and pricing of the offering. These releases provided transparency for shareholders.
This article is for informational purposes only and does not constitute financial advice. Please consult a licensed financial adviser before making investment decisions.






Please wait processing your request...